Medications for Opioid Use Disorder in the Criminal/Legal System: Knowledge,Beliefs,and Attitudes Among Rural Community-Based Stakeholders

Abstract

The aim of this study was to describe rural community stakeholders’ attitudes and perceptions of providing medication for opioid use disorder (MOUD) to individuals in the criminal/legal system. Data were utilized from a technical assistance initiative aimed at strengthening community-based OUD treatment within criminal/legal systems. A mixed-methods approach was applied. Survey responses were used to compare stakeholders’ who had and had not attended an MOUD training, and semistructured interviews were conducted with a convenience sample of rural criminal/legal and treatment stakeholders. MOUD training was associated with endorsing the effectiveness of methadone, oral naltrexone, and injectable naltrexone. Three primary themes emerged from the stakeholder interviews: 1) acceptance of MOUD uptake; 2) stigma of MOUD and diversion concerns; and 3) gaps in MOUD treatment. Most interviewees noted that there is a scarcity of treatment options in their community, and among the existing services, there are considerable barriers to care.

Keywords

bprenorphine criminal/legal system mixed-methods medication for opioid use disorder

Get full access to this article

View all access options for this article.

References

Alex

Weiss

D. B.

Kaba

Rosner

Lee

Lim

MacDonald

(2017). Death After Jail Release: Matching to Improve Care Delivery. Journal of Correctional Health Care, 23(1), 83–87. https://doi.org/10.1177/1078345816685311

AlYahmady

H. H.

Al Abri

S. S.

(2013). Using Nvivo for Data Analysis in Qualitative Research. International Interdisciplinary Journal of Education, 2(2), 181–186. https://doi.org/10.12816/0002914

Andraka-Christou

Atkins

(2020). Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff. The American Journal of Drug and Alcohol Abuse, 46(6), 749–760. https://doi.org/10.1080/00952990.2020.1807559

Andraka-Christou

Capone

M. J.

(2018). A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. The International Journal on Drug Policy, 54, 9–17. https://doi.org/10.1016/j.drugpo.2017.11.021

Andrilla

C. H. A.

Coulthard

Larson

E. H.

(2017). Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder. The Annals of Family Medicine, 15(4), 359–362. https://doi.org/10.1370/afm.2099

Andrilla

C. H. A.

Moore

T. E.

Patterson

D. G.

Larson

E. H.

(2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health, 35(1), 108–112. https://doi.org/10.1111/jrh.12307

Beachler

Zeller

T. A.

Heo

Lanzillotta‐Rangeley

Litwin

A. H.

(2021). Community attitudes toward opioid use disorder and medication for opioid use disorder in a rural appalachian county. The Journal of Rural Health. ■■■. https://doi.org/10.1111/jrh.12503

Binswanger

I. A.

Blatchford

P. J.

Mueller

S. R.

Stern

M. F.

(2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159(9), 592–600. https://doi.org/10.7326/0003-4819-159-9-201311050-00005

Binswanger

I. A.

Stern

M. F.

Deyo

R. A.

Heagerty

P. J.

Cheadle

Elmore

J. G.

Koepsell

T. D.

(2007). Release from Prison—a high risk of death for former inmates. New England Journal of Medicine, 356(2), 157–165. https://doi.org/10.1056/NEJMsa064115

10.

Brown

J. D.

Goodin

A. J.

Talbert

J. C.

(2018). Rural and appalachian disparities in neonatal abstinence syndrome incidence and access to opioid abuse treatment. The Journal of Rural Health, 34(1), 6–13. https://doi.org/10.1111/jrh.12251

11.

Browne

Priester

M. A.

Clone

Iachini

DeHart

Hock

(2016). Barriers and facilitators to substance use treatment in the rural South: A qualitative study. The Journal of Rural Health, 32(1), 92–101. https://doi.org/10.1111/jrh.12129

12.

Burgess

Bauer

Gallagher

Karstens

Lavoie

Ahrens

O’Connor

(2021). Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis. Journal of Substance Abuse Treatment, 130, 108488. https://doi.org/10.1016/j.jsat.2021.108488

13.

Carlson

R. G.

Daniulaityte

Silverstein

S. M.

Nahhas

R. W.

Martins

S. S.

(2020). Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose? International Journal of Drug Policy, 79, 102722. https://doi.org/10.1016/j.drugpo.2020.102722

14.

Carroll

Rich

Green

(2018). The more things change: buprenorphine/naloxone diversion continues while treatment remains inaccessible. Journal of Addiction Medicine, 12(6), 459–465. https://doi.org/10.1097/ADM.0000000000000436

15.

Centers for Disease Control & Prevention (2020). Overdose Deaths Accelerating During COVID-19. CDC Newsroom. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html

16.

Charmaz

(2017). The power of constructivist grounded theory for critical inquiry. Qualitative Inquiry, 23(1), 34–45. https://doi.org/10.1177/1077800416657105

17.

Cicero

T. J.

Ellis

M. S.

Chilcoat

H. D.

(2018). Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence, 193, 117–123. https://doi.org/10.1016/j.drugalcdep.2018.09.007

18.

Compton

W. M.

Jones

C. M.

Baldwin

G. T.

(2016). Relationship between nonmedical prescription-opioid use and heroin use. New England Journal of Medicine, 374(2), 154–163. https://doi.org/10.1056/NEJMra1508490

19.

Cooper

H. L.

Cloud

D. H.

Freeman

P. R.

Fadanelli

Green

Van Meter

Young

A. M.

(2020). Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. International Journal of Drug Policy, 85, 102701. https://doi.org/10.1016/j.drugpo.2020.102701

20.

Crapanzano

K. A.

Hammarlund

Ahmad

Hunsinger

Kullar

(2018). The association between perceived stigma and substance use disorder treatment outcomes: A review. Substance Abuse and Rehabilitation, 10, 1–12. https://doi.org/10.2147/SAR.S183252

21.

DeFlavio

Rolin

S. A.

Nordstrom

B. R.

Louis A Kazal

(2015). Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians . https://doi.org/10.22605/RRH3019

22.

del Pozo

Rich

J. D.

(2020). Revising our attitudes towards agonist medications and their diversion in a time of pandemic. Journal of Substance Abuse Treatment, 119, 108139. https://doi.org/10.1016/j.jsat.2020.108139

23.

Dew

Elifson

Dozier

(2007). Social and environmental factors and their influence on drug use vulnerability and resiliency in rural populations. The Journal of Rural Health, 23(s1), 16–21. https://doi.org/10.1111/j.1748-0361.2007.00119.x

24.

Dunn

K. E.

Barrett

F. S.

Yepez-Laubach

Meyer

A. C.

Hruska

B. J.

Petrush

Bigelow

G. E.

(2016). Opioid overdose experience, risk behaviors, and knowledge in drug users from a rural versus an urban setting. Journal of Substance Abuse Treatment, 71, 1–7. https://doi.org/10.1016/j.jsat.2016.08.006

25.

Ellis

A. R.

Konrad

T. R.

Thomas

K. C.

Morrissey

J. P.

(2009). County-level estimates of mental health professional supply in the United States. Psychiatric Services, 60(10), 1315–1322. https://doi.org/10.1176/ps.2009.60.10.1315

26.

Evans

E. A.

Zhu

Yoo

Huang

Hser

Y.-I.

(2019). Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction (Abingdon, England), 114(8), 1396–1404. https://doi.org/10.1111/add.14620

27.

Ezell

J. M.

Walters

Friedman

S. R.

Bolinski

Jenkins

W. D.

Pho

M. T.

(2021). Stigmatize the use, not the user? Attitudes on opioid use, drug injection, treatment, and overdose prevention in rural communities. Social Science & Medicine, 268, 113470. https://doi.org/10.1016/j.socscimed.2020.113470

28.

Fiscella

Wakeman

S. E.

Beletsky

(2018). Implementing opioid agonist treatment in correctional facilities. JAMA Internal Medicine, 178(9), 1153–1154. https://doi.org/10.1001/jamainternmed.2018.3504

29.

Ford

J. H.

Osborne

E. L.

Assefa

M. T.

McIlvaine

A. M.

King

A. M.

Campbell

McGovern

M. P.

(2018). Using NIATx strategies to implement integrated services in routine care: A study protocol. BMC Health Services Research, 18(1), 431. https://doi.org/10.1186/s12913-018-3241-4

30.

Green

T. C.

Clarke

Brinkley-Rubinstein

Marshall

B. D. L.

Alexander-Scott

Boss

Rich

J. D.

(2018). Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry, 75(4), 405–407. https://doi.org/10.1001/jamapsychiatry.2017.4614

31.

Hedegaard

Warner

Miniño

A. M.

(2017). Drug overdose deaths in the United States, 1999–2015

32.

Ibragimov

Young

A. M.

Cooper

H. L. F.

(2020). Understanding rural risk environments for drug-related harms: Progress, challenges, and steps forward. The International Journal on Drug Policy, 85, 102926. https://doi.org/10.1016/j.drugpo.2020.102926

33.

Jones

E. B.

(2018). Medication-assisted opioid treatment prescribers in federally qualified health centers: Capacity lags in rural areas. The Journal of Rural Health, 34(1), 14–22. https://doi.org/10.1111/jrh.12260

34.

Kaufman

B. G.

Thomas

S. R.

Randolph

R. K.

Perry

J. R.

Thompson

K. W.

Holmes

G. M.

Pink

G. H.

(2016). The rising rate of rural hospital closures. The Journal of Rural Health, 32(1), 35–43. https://doi.org/10.1111/jrh.12128

35.

Lefebvre

R. C.

Chandler

R. K.

Helme

D. W.

Kerner

Mann

Stein

M. D.

Rodgers

(2020). Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing communities study. Drug and Alcohol Dependence, 217, 108338. https://doi.org/10.1016/j.drugalcdep.2020.108338

36.

Lister

J. J.

Weaver

Ellis

J. D.

Himle

J. A.

Ledgerwood

D. M.

(2020). A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. The American Journal of Drug and Alcohol Abuse, 46(3), 273–288. https://doi.org/10.1080/00952990.2019.1694536

37.

McCarty

Gustafson

Capoccia

V. A.

Cotter

(2009). Improving care for the treatment of alcohol and drug disorders. The Journal of Behavioral Health Services & Research, 36(1), 52–60. https://doi.org/10.1007/s11414-008-9108-4

38.

McCarty

Rieckmann

Green

Gallon

Knudsen

(2004). Training rural practitioners to use buprenorphine: Using the change book to facilitate technology transfer. Journal of Substance Abuse Treatment, 26(3), 203–208. https://doi.org/10.1016/S0740-5472(03)00247-2

39.

McGinty

E. E.

Barry

C. L.

(2020). Stigma reduction to combat the addiction crisis—developing an evidence base. New England Journal of Medicine, 382(14), 1291–1292. https://doi.org/10.1056/NEJMp2000227

40.

Pallant

(2003). SPSS survival manual: A step-by-step guide to data analysis using SPSS for Windows (Versions 10 and 11). [applies to SPSS for Windows up to Version 11] (Reprinted). Open Univ. Press

41.

Pozo

B. D.

Krasner

L. S.

George

S. F.

(2020). Decriminalization of diverted buprenorphine in burlington, vermont and philadelphia: An intervention to reduce opioid overdose deaths. The Journal of Law, Medicine & Ethics, 48(2), 373–375. https://doi.org/10.1177/1073110520935353

42.

Quest

T. L.

Merrill

J. O.

Roll

Saxon

A. J.

Rosenblatt

R. A.

(2012). Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adopters. Journal of Opioid Management, 8(1), 29–38. https://doi.org/10.5055/jom.2012.0093

43.

Richard

E. L.

Schalkoff

C. A.

Piscalko

H. M.

Brook

D. L.

Sibley

A. L.

Lancaster

K. E.

V. F.

(2020). “You are not clean until you’re not on anything”: Perceptions of medication-assisted treatment in rural Appalachia. International Journal of Drug Policy, 85, 102704. https://doi.org/10.1016/j.drugpo.2020.102704

44.

Rigg

K. K.

Monnat

S. M.

Chavez

M. N.

(2018). Opioid-related mortality in rural America: Geographic heterogeneity and intervention strategies. International Journal of Drug Policy, 57, 119–129. https://doi.org/10.1016/j.drugpo.2018.04.011

45.

Rosenblatt

R. A.

Andrilla

C. H. A.

Catlin

Larson

E. H.

(2015). Geographic and specialty distribution of US physicians trained to treat opioid use disorder. The Annals of Family Medicine, 13(1), 23–26. https://doi.org/10.1370/afm.1735

46.

Roy

É.

Arruda

Bruneau

Jutras-Aswad

(2016). Epidemiology of injection drug use: New trends and prominent issues. The Canadian Journal of Psychiatry, 61(3), 136–144. https://doi.org/10.1177/0706743716632503

47.

Saldaña

(2015). The coding manual for qualitative researchers. Sage

48.

Silverstein

S. M.

Daniulaityte

Miller

S. C.

Martins

S. S.

Carlson

R. G.

(2020). On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. Drug and Alcohol Dependence, 210, 107958. https://doi.org/10.1016/j.drugalcdep.2020.107958

49.

Snell-Rood

Staton-Tindall

Victor

(2016). Incarcerated women’s relationship-based strategies to avoid drug use after community re-entry. Women & Health, 56(7), 843–858. https://doi.org/10.1080/03630242.2015.1118732

50.

Tomar

Brinkley-Rubinstein

Ghezzi

M. A.

Van Deinse

T. B.

Burgin

Cuddeback

G. S.

(2020). Internalized stigma and its correlates among justice-involved individuals with mental illness. International Journal of Mental Health, 49(2), 201–211. https://doi.org/10.1080/00207411.2019.1703358

51.

Tsai

A. C.

Kiang

M. V.

Barnett

M. L.

Beletsky

Keyes

K. M.

McGinty

E. E.

Venkataramani

A. S.

(2019). Stigma as a fundamental hindrance to the United States opioid overdose crisis response. Plos Medicine, 16(11), Article e1002969. https://doi.org/10.1371/journal.pmed.1002969

52.

Turan

Budhwani

Fazeli

P. L.

Browning

W. R.

Raper

J. L.

Mugavero

M. J.

Turan

J. M.

(2017). How does stigma affect people living with HIV? The mediating roles of internalized and anticipated HIV stigma in the effects of perceived community stigma on health and psychosocial outcomes. AIDS and Behavior, 21(1), 283–291. https://doi.org/10.1007/s10461-016-1451-5

53.

Van Brakel

W. H.

Cataldo

Grover

Kohrt

B. A.

Nyblade

Stockton

Yang

L. H.

Yang

(2019). Out of the silos: identifying cross-cutting features of health-related stigma to advance measurement and intervention. BMC Medicine, 17(1), 1–17. https://doi.org/10.1186/s12916-018-1245-x

54.

Victor

G. A.

Bailey

Ray

(2021). Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose. Substance Use & Misuse. https://www.tandfonline.com/doi/abs/10.1080/10826084.2021.1901933

55.

Victor

Sightes

Watson

D. P.

Ray

Bailey

Robision

Fears

Salyers

(2021). Designing and implementing an intervention for returning citizens living with substance use disorder: Discovering the benefits of peer recovery coach involvement in pilot clinical trial decision-making. Journal of Offender Rehabilitation, 60(2), 138–158. https://doi.org/10.1080/10509674.2020.1863301

56.

Victor

G. A.

Walker

Cole

Logan

T. K.

(2017). Opioid analgesics and heroin: Examining drug misuse trends among a sample of drug treatment clients in Kentucky. International Journal of Drug Policy, 46, 1–6. https://doi.org/10.1016/j.drugpo.2017.01.008

57.

Volkow

N. D.

McLellan

A. T.

(2016). Opioid abuse in chronic pain—misconceptions and mitigation strategies. The New England Journal of Medicine, 374(13), 1253–1263. https://doi.org/10.1056/NEJMra1507771

58.

Wakeman

S. E.

Rich

J. D.

(2015). Addiction treatment within U.S. correctional facilities: Bridging the gap between current practice and evidence-based care. Journal of Addictive Diseases, 34(2–3), 220–225. https://doi.org/10.1080/10550887.2015.1059217

59.

Wakeman

S. E.

Rich

J. D.

(2018). Barriers to medications for addiction treatment: How stigma kills. Substance Use & Misuse, 53(2), 330–333. https://doi.org/10.1080/10826084.2017.1363238

60.

Wang

K. H.

Becker

W. C.

Fiellin

D. A.

(2013). Prevalence and correlates for nonmedical use of prescription opioids among urban and rural residents. Drug and Alcohol Dependence, 127(1-3), 156–162. https://doi.org/10.1016/j.drugalcdep.2012.06.027

61.

Wenger

L. D.

Lopez

A. M.

Kral

A. H.

Bluthenthal

R. N.

(2016). Moral ambivalence and the decision to initiate others into injection drug use: A qualitative study in two California cities. International Journal of Drug Policy, 37, 42–51. https://doi.org/10.1016/j.drugpo.2016.07.008

62.

Wicks

(2017). The coding manual for qualitative researchers. In: The Qualitative Research in Organizations and Management(3rd ed.), 12, pp. 169–170. https://doi.org/10.1108/QROM-08-2016-1408

63.

Wunsch

M. J.

Nakamoto

Behonick

Massello

(2009). Opioid deaths in rural virginia: A description of the high prevalence of accidental fatalities involving prescribed medications. The American Journal on Addictions, 18(1), 5–14. https://doi.org/10.1080/10550490802544938

64.

Young

A. M.

Havens

J. R.

Leukefeld

C. G.

(2010). Route of administration for illicit prescription opioids: A comparison of rural and urban drug users. Harm Reduction Journal, 7(1), 24. https://doi.org/10.1186/1477-7517-7-24